NCT03330847 2026-03-10To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.AstraZenecaPhase 2 Active not recruiting273 enrolled 22 charts
NCT05514132 2026-03-09A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursAstraZenecaPhase 1 Active not recruiting14 enrolled